← Back to Search

Monoclonal Antibodies

ARGX-117 for Delayed Graft Function (VARVARA Trial)

Phase 2
Recruiting
Research Sponsored by argenx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 52 weeks
Awards & highlights

VARVARA Trial Summary

This trial is looking at how safe and effective a drug called ARGX-117 is in kidney transplant patients who are at risk for delayed graft function.

Who is the study for?
This trial is for deceased donor kidney transplant recipients aged 18-70, at risk for delayed graft function. Participants must have been on stable dialysis for 3+ months, weigh less than 120 kg with a BMI under 40, and agree to use contraception. They should be getting their first or second kidney transplant and have had necessary vaccinations including SARS-CoV-2.Check my eligibility
What is being tested?
The study tests ARGX-117's safety and effectiveness in preventing delayed graft function after a kidney transplant from a deceased donor. It's a phase 2 trial where participants are randomly given either ARGX-117 or a placebo to compare outcomes.See study design
What are the potential side effects?
Potential side effects of ARGX-117 aren't specified here but may include typical drug reactions such as allergic responses, site injection issues, general discomforts like headaches or nausea, and possibly immune system-related effects.

VARVARA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
eGFR at 24 weeks posttransplant
Secondary outcome measures
CRR at 72 hours and on study day 8 (posttransplant day 7)
Change from baseline in free C2, total C2, and CH50 activity
Dialysis-free survival through 52 weeks posttransplant
+9 more

VARVARA Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ARGX-117Experimental Treatment1 Intervention
Patients receiving ARGX-117 intravenous infusions
Group II: PlaceboPlacebo Group1 Intervention
Patients receiving placebo intravenous infusions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARGX-117
2020
Completed Phase 1
~110

Find a Location

Who is running the clinical trial?

argenxLead Sponsor
63 Previous Clinical Trials
10,074 Total Patients Enrolled
~68 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top